

# Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/S62D8B27392FEN.html>

Date: October 2022

Pages: 113

Price: US\$ 3,500.00 (Single User License)

ID: S62D8B27392FEN

## Abstracts

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### SUMMARY

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Soluble guanylyl cyclase (sGC) is the known receptor for nitric oxide. Binding of nitric oxide to the heme moiety of the cyclase induces its capacity to synthesize the second messenger cGMP. Although the changes in the state of the heme moiety upon exposure of enzyme to NO and its correlation to the stimulation of sGC catalytic activity.

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) pipeline Target constitutes close to 31 molecules. Out of which approximately 28 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 4, 5, 6 and 13 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Cardiovascular, Ophthalmology, Metabolic Disorders, Genito Urinary System And Sex Hormones, Infectious Disease, Oncology, Gastrointestinal, Respiratory, Central Nervous System, Hematological Disorders, Dermatology, Immunology and Musculoskeletal Disorders which include indications Glaucoma, Pulmonary Arterial Hypertension, Chronic Kidney Disease (Chronic Renal Failure), Coronavirus Disease 2019 (COVID-19), Chronic Thromboembolic Pulmonary Hypertension, Diabetic Nephropathy, Hypertension, Neuroinflammation, Ocular Hypertension, Pulmonary Hypertension, Sickle Cell Disease With Vaso-Occlusive Crisis, Acute Heart Failure, Acute Respiratory Distress Syndrome,

Alzheimer's Disease, Asthma, Brain Cancer, Chronic Obstructive Pulmonary Disease (COPD), Cirrhosis, Cognitive Impairment Associated With Schizophrenia (CIAS), Colorectal Cancer, Critical Limb Ischemia, Diabetic Foot Ulcers, Diabetic Retinopathy, Diastolic Heart Failure, Dry (Atrophic) Macular Degeneration, Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Hypertension, Inflammatory Bowel Disease, Ischemic Stroke, Kidney Disease (Nephropathy), Liver Fibrosis, MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes), Mitochondrial Diseases, Mycobacterium Infections, Non-Alcoholic Steatohepatitis (NASH), Non-Proliferative Diabetic Retinopathy (NPDR), Open-Angle Glaucoma, Osteoporosis, Pancreatic Cancer, Peripheral Arterial Disease (PAD)/Peripheral Vascular Disease (PVD), Pneumonia, Portal Hypertension, Pressure Ulcers, Prostate Cancer, Raynauds Disease, Schizophrenia, Skin Ulcers, Stable Angina, Stroke, Systemic Sclerosis (Scleroderma), Triple-Negative Breast Cancer (TNBC), Unspecified Cardiovascular Disorders and Vascular Dementias.

The latest report Soluble Guanylate Cyclase - Drugs In Development, 2022, outlays comprehensive information on the Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Soluble Guanylate Cyclase (sGC or EC 4.6.1.2)

The report reviews Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific

## sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics and enlists all their major and minor projects

The report assesses Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Overview

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Companies Involved in Therapeutics Development

Akebia Therapeutics Inc

AntiRadical Therapeutics LLC

Bayer AG

Boehringer Ingelheim International GmbH

Cyclerion Therapeutics Inc

Gurus BioPharm Inc

Innovative Pharmacology Research

Merck & Co Inc

NicOx SA

Nitric Oxide Innovations LLC

Novartis AG

Novoteris LLC

Toa Eiyo Ltd

Topadur Pharma AG

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Drug Profiles

A-8R - Drug Profile

Product Description

Mechanism Of Action

BAY-1211163 - Drug Profile

Product Description

Mechanism Of Action

History of Events

BAY-1237592 - Drug Profile

Product Description

Mechanism Of Action

History of Events

BAY-3283142 - Drug Profile

Product Description

Mechanism Of Action

History of Events

BAY-546544 - Drug Profile

Product Description

Mechanism Of Action

History of Events

BI-685509 - Drug Profile

Product Description

Mechanism Of Action

History of Events

CY-3018 - Drug Profile

Product Description

Mechanism Of Action

History of Events

CY-6463 - Drug Profile

Product Description

Mechanism Of Action

History of Events

GRS - Drug Profile

Product Description

Mechanism Of Action

GUR-501 - Drug Profile

Product Description

Mechanism Of Action

History of Events

GUR-602 - Drug Profile

Product Description

Mechanism Of Action

History of Events

MK-5475 - Drug Profile

Product Description

Mechanism Of Action

History of Events

mosliciguat - Drug Profile

Product Description

Mechanism Of Action

naproxcinod - Drug Profile

Product Description

Mechanism Of Action

History of Events

NCX-470 - Drug Profile

Product Description

Mechanism Of Action

History of Events

NCX-667 SR - Drug Profile

Product Description

Mechanism Of Action

History of Events

nitric oxide - Drug Profile

Product Description

Mechanism Of Action

History of Events

nitric oxide - Drug Profile

Product Description

Mechanism Of Action

History of Events

olinciguat - Drug Profile

Product Description

Mechanism Of Action

History of Events

praliciguat - Drug Profile

Product Description

Mechanism Of Action

History of Events

riociguat - Drug Profile

Product Description

Mechanism Of Action

History of Events

runcaciguat - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Activate sGC for Osteoporosis - Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Activate Soluble Guanylate Cyclase for Glaucoma - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Activate Soluble Guanylate Cyclase for Glaucoma - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Activate Soluble Guanylate Cyclase for Oncology - Drug Profile

Product Description

Mechanism Of Action

TOPN-53 - Drug Profile

Product Description

Mechanism Of Action

History of Events

TOPT-5 - Drug Profile

Product Description

Mechanism Of Action

TOPV-122 - Drug Profile

Product Description

Mechanism Of Action

History of Events

TY-55002 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Vacno - Drug Profile

Product Description

Mechanism Of Action

History of Events

vericiguat - Drug Profile

Product Description

Mechanism Of Action

History of Events

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Dormant Products

Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Discontinued Products



## Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) - Product Development Milestones Featured News & Press Releases

Oct 06, 2022: Cycleron announces mitochondrial disease-focused corporate strategy

Sep 29, 2022: Bayer launches vericiguat (Verquvo) in India, the first novel treatment approved to reduce the risk of cardiovascular deaths and repeated hospitalizations

Sep 19, 2022: Nicox announces last patients complete final visit in NCX 470 phase 3 Mont Blanc glaucoma trial

Jul 28, 2022: Cycleron Therapeutics announces positive topline clinical data for CY6463 in patients with Cognitive Impairment Associated with Schizophrenia (CIAS)

Jul 07, 2022: Nicox announces publication of NCX 470 results demonstrating improvements to ocular hemodynamics and retinal cell physiology

Jun 28, 2022: Cycleron Therapeutics provides additional positive CY6463 MELAS clinical data at a webina hosted by United Mitochondrial Disease Foundation

Jun 22, 2022: Cycleron Therapeutics to discuss CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation

Jun 17, 2022: Cycleron Therapeutics announces CY6463 data demonstrating improved cellular energetics in preclinical models of mitochondrial disease

Jun 10, 2022: Cycleron Therapeutics announces positive topline clinical data for CY6463 in MELAS Patients at UMDF Mitochondrial Medicine 2022 Symposium

Jun 06, 2022: Cycleron Therapeutics to share CY6463 MELAS topline study results, CHOP to present CY6463 preclinical data at UMDF Mitochondrial Medicine 2022 Symposium

Jun 03, 2022: Nicox accelerates topline results from NCX 470 Mont Blanc phase 3 glaucoma trial to November 2022

May 19, 2022: Verquvo (vericiguat) approved in China to treat patients with chronic heart failure and reduced ejection fraction

May 17, 2022: New therapeutic option to reduce risk of cardiovascular deaths and repeated hospitalizations among adult heart failure patients approved in Singapore

May 04, 2022: Cycleron announces CY6463 clinical pipeline progress

May 02, 2022: Nicox at ARVO 2022: Presentation of new non-clinical evidence of improved hemodynamic and retinal cell physiology on NCX

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer



## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Akebia Therapeutics Inc, 2022

Pipeline by AntiRadical Therapeutics LLC, 2022

Pipeline by Bayer AG, 2022

Pipeline by Boehringer Ingelheim International GmbH, 2022

Pipeline by Cycleron Therapeutics Inc, 2022

Pipeline by Gurus BioPharm Inc, 2022

Pipeline by Innovative Pharmacology Research, 2022

Pipeline by Merck & Co Inc, 2022

Pipeline by NicOx SA, 2022

Pipeline by Nitric Oxide Innovations LLC, 2022

Pipeline by Novartis AG, 2022

Pipeline by Novoteris LLC, 2022

Pipeline by Toa Eiyo Ltd, 2022

Pipeline by Topadur Pharma AG, 2022

Dormant Products, 2022

Discontinued Products, 2022

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

## I would like to order

Product name: Soluble Guanylate Cyclase (sGC or EC 4.6.1.2) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/S62D8B27392FEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S62D8B27392FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

